Back to Search
Start Over
TNF-α induces expression of the circadian clock gene Bmal1 via dual calcium-dependent pathways in rheumatoid synovial cells.
- Source :
-
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2018 Jan 08; Vol. 495 (2), pp. 1675-1680. Date of Electronic Publication: 2017 Dec 05. - Publication Year :
- 2018
-
Abstract
- Tumor necrosis factor (TNF)-α is responsible for expressions of several clock genes and affects joint symptoms of rheumatoid arthritis (RA) with diurnal fluctuation. We tried to determine the mechanism involved in over-expression of Bmal1, induced by TNF-α, in primary cultured rheumatoid synovial cells. Cells were incubated with intra-cellular Ca <superscript>2+</superscript> chelator BAPTA-AM, calcineurin inhibitor FK506 and p300/CBP (CREB binding protein) inhibitor C646, respectively, or transfected with p300 and CBP small interfering RNA (siRNA) before stimulation with TNF-α. Oscillation phase and amplitude of Bmal1, transcriptional activator Rorα, transcriptional repressor Rev-erbα, and histone acetyltransferases (p300 and Cbp) were evaluated by quantitative real-time PCR. As results, TNF-α did not influence the oscillation phase of Rev-erbα, while enhanced those of Rorα, resulting in over-expression of Bmal1. When Ca <superscript>2+</superscript> influx was inhibited by BAPTA-AM, TNF-α-mediated up-regulation of Rorα was cancelled, however, that of Bmal1 was still apparent. When we further explored another pathway between TNF-α and Bmal1, TNF-α suppressed the expression of Rev-erbα in the absence of Ca <superscript>2+</superscript> influx, as well as those of p300 and Cbp genes. Finally, actions of TNF-α, in increasing Bmal1/Rorα and decreasing Rev-erbα, were cancelled by C646 treatment or silencing of both p300 and Cbp. In conclusion, we determined a novel role of TNF-α in inducing Bmal1 via dual calcium dependent pathways; Rorα was up-regulated in the presence of Ca <superscript>2+</superscript> influx and Rev-erbα was down-regulated in the absence of that. Results proposed that inhibition of p300/CBP could be new therapeutic targets for RA.<br /> (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Arthritis, Rheumatoid pathology
Benzoates pharmacology
CREB-Binding Protein antagonists & inhibitors
CREB-Binding Protein genetics
Calcium Chelating Agents pharmacology
Cells, Cultured
E1A-Associated p300 Protein antagonists & inhibitors
E1A-Associated p300 Protein genetics
Egtazic Acid analogs & derivatives
Egtazic Acid pharmacology
Gene Expression drug effects
Humans
Nitrobenzenes
Nuclear Receptor Subfamily 1, Group D, Member 1 genetics
Nuclear Receptor Subfamily 1, Group F, Member 1 genetics
Pyrazoles pharmacology
Pyrazolones
RNA, Messenger genetics
RNA, Messenger metabolism
RNA, Small Interfering genetics
Synovial Membrane drug effects
Synovial Membrane pathology
Tumor Necrosis Factor-alpha pharmacology
ARNTL Transcription Factors genetics
Arthritis, Rheumatoid genetics
Arthritis, Rheumatoid metabolism
Calcium Signaling drug effects
Circadian Clocks genetics
Synovial Membrane metabolism
Tumor Necrosis Factor-alpha metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1090-2104
- Volume :
- 495
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Biochemical and biophysical research communications
- Publication Type :
- Academic Journal
- Accession number :
- 29217191
- Full Text :
- https://doi.org/10.1016/j.bbrc.2017.12.015